NurExone Biologic Inc. (TSXV:NRX) is a biopharmaceutical company specializing in the development of exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, aims to promote neuron regeneration and functional recovery in patients with acute spinal cord injuries.

TSX Venture 50™ is a ranking of the 50 top-performing companies on TSX Venture Exchange over the last year. Companies are ranked based on three equally-weighted criteria of one-year share price appreciation, market capitalization increase, and Canadian consolidated trading value.

Explore the 2025 list and related content at https://www.tsx.com/venture50.